Glaukos Co. (NYSE:GKOS) Holdings Lifted by Commonwealth Equity Services LLC

Commonwealth Equity Services LLC grew its holdings in shares of Glaukos Co. (NYSE:GKOS) by 12.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,770 shares of the medical instruments supplier’s stock after buying an additional 661 shares during the period. Commonwealth Equity Services LLC’s holdings in Glaukos were worth $865,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in GKOS. Swiss National Bank raised its stake in Glaukos by 9.9% during the 4th quarter. Swiss National Bank now owns 108,100 shares of the medical instruments supplier’s stock valued at $16,209,000 after acquiring an additional 9,700 shares in the last quarter. HighTower Advisors LLC increased its holdings in shares of Glaukos by 2.8% during the fourth quarter. HighTower Advisors LLC now owns 3,298 shares of the medical instruments supplier’s stock valued at $495,000 after purchasing an additional 91 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Glaukos by 36.4% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,939 shares of the medical instruments supplier’s stock valued at $2,240,000 after purchasing an additional 3,983 shares in the last quarter. PNC Financial Services Group Inc. lifted its holdings in Glaukos by 817.2% in the fourth quarter. PNC Financial Services Group Inc. now owns 34,541 shares of the medical instruments supplier’s stock worth $5,179,000 after purchasing an additional 30,775 shares during the period. Finally, Lisanti Capital Growth LLC grew its position in Glaukos by 39.7% in the 4th quarter. Lisanti Capital Growth LLC now owns 29,790 shares of the medical instruments supplier’s stock valued at $4,467,000 after buying an additional 8,460 shares in the last quarter. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Glaukos Trading Down 1.3 %

NYSE:GKOS opened at $97.15 on Wednesday. The stock has a fifty day simple moving average of $128.12 and a 200 day simple moving average of $135.38. The firm has a market capitalization of $5.50 billion, a price-to-earnings ratio of -33.85 and a beta of 0.99. Glaukos Co. has a 1-year low of $88.16 and a 1-year high of $163.71. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19.

Glaukos (NYSE:GKOS) last announced its earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.02). Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. The firm had revenue of $105.50 million during the quarter, compared to analyst estimates of $100.72 million. Sell-side analysts forecast that Glaukos Co. will post -1.08 earnings per share for the current year.

Insiders Place Their Bets

In other Glaukos news, insider Tomas Navratil sold 3,416 shares of Glaukos stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $147.14, for a total transaction of $502,630.24. Following the transaction, the insider now owns 72,437 shares of the company’s stock, valued at $10,658,380.18. The trade was a 4.50 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Alex R. Thurman sold 1,520 shares of the stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $106.84, for a total transaction of $162,396.80. Following the completion of the sale, the chief financial officer now directly owns 53,431 shares of the company’s stock, valued at $5,708,568.04. This trade represents a 2.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 6.40% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have commented on GKOS. Piper Sandler restated an “overweight” rating and set a $180.00 price target (up from $140.00) on shares of Glaukos in a research report on Monday, January 27th. UBS Group started coverage on Glaukos in a report on Friday, December 6th. They set a “buy” rating and a $182.00 target price on the stock. Wells Fargo & Company lifted their price target on Glaukos from $153.00 to $160.00 and gave the company an “overweight” rating in a research report on Friday, February 21st. Citigroup raised Glaukos from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $132.00 to $162.00 in a research note on Wednesday, December 11th. Finally, Mizuho raised Glaukos from a “neutral” rating to an “outperform” rating and raised their target price for the company from $140.00 to $200.00 in a research note on Wednesday, February 19th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Glaukos currently has an average rating of “Moderate Buy” and a consensus target price of $163.25.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.